| abstract |
FIELD: chemistry. n SUBSTANCE: invention relates to novel polyheterocyclic compounds of formulas Ia or Ib, given below, stereoisomers, pharmaceutically acceptable salts or their mixture, where m=0.1 or 2; n=0.1 or 2; p=0.1 or 2; q=0.1 or 2; r=0. 1, 2 or 3; stands for a single bond or a double bond; and stands for a double bond in a macrocyclic internal combination with cyclopropyl formyl; stands for a single bond in a cycle D, E, E 1 and G, where D and G independently stand for oxygen, E and E 1 independently stand for C(Ra)(Rb); R 10 stands for hydrogen; Ra, Rb and Rc independently on each other stand for hydrogen; when r=0 E is absent, D and E 1 are directly bound; L stands for methylene (CRbRc); T stands for nitrogen (N) or CH; U stands for carbon (C); W stands for oxygen; X stands for oxygen; Y stands for nitrogen (N) or CH; Z stands for OH; C 1 -C 20 alkyl-sulphonylamido, C 3 -C 20 -cycloalkyl-sulphonylamido; R 1 and R 2 independently stand for C 1 -C 20 -alkyl, C 3 -C 20 cycloalkyl, C 6 -C 12 arylamine, C 1 -C 20 alkoxycarbonyl-amino, C 2 -C 20 heterocyclic sulphonylamide ring; R 3 , R 4 , R 5 , R 6 - independently stand for H; R 7 , R 8 and R 9 independently stand for H. The compounds inhibit replication of protease NS3 of the hepatitis C virus. n EFFECT: improved properties of the compounds. n 7 cl, 1 tbl, 11 dwg, 118 ex |